-
Electronic (PDF)
-
Site License
-
Enterprisewide
The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
GBI Research, December 2009, Pages: 102
“The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis” provides in-depth analysis of unmet needs, drivers and barriers that impact the global cardiovascular diseases therapeutics market. The report analyzes the markets for cardiovascular disease therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
Scope
The scope of this report includes:
- Annualized market data for the cardiovascular diseases therapeutics market from 2000 to 2008, forecast forward to 2015
- Analysis of the leading therapeutic segments including hypertension, dyslipidemia and thrombosis
- Analysis of the cardiovascular diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
- Market characterization of the cardiovascular diseases therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns
- Key drivers and barriers that have a significant impact on the market
- Coverage of pipeline molecules in various phases of drug development
- Competitive benchmarking of leading companies. The key companies studied in this report are Novartis AG, Sanofi-aventis, Pfizer Inc and Merck & Co
- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global cardiovascular diseases therapeutics market
Reasons to buy
The report will aid Business Development and marketing executives strategizing their product launches. It will allow you to;
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the cardiovascular diseases therapeutics market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the cardiovascular diseases therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global cardiovascular diseases therapeutics landscape? – Identify, understand and capitalize.
1 Contents
1.1 List of Tables
1.2 List of Figures
2 Global Cardiovascular Therapeutics Market: Scope of Research
2.1 Introduction
2.2 GBI Research Report Guidance
3 Global Cardiovascular Therapeutics Market: Market Characterization
3.1 Market Forecasts
3.2 Branded Vs Generics
3.3 Average Cost of Therapy
3.4 Volume
3.5 Usage Patterns
3.5.1 Diseased Population
3.5.2 Treatment Seeking Population
3.5.3 Diagnosis Population
3.5.4 Prescription Population
3.5.5 Usage Patterns
3.5.6 Geographical Distribution
4 Global Cardiovascular Therapeutics Market: US Market
4.1 Market Overview
4.2 Market Forecasts
4.3 Average Cost of Therapy
4.4 Volume
4.5 Usage Patterns
4.5.1 Diseased Population
4.5.2 Treatment Seeking Population
4.5.3 Diagnosis Population
4.5.4 Prescription Population
4.5.5 Usage Patterns
5 Global Cardiovascular Therapeutics Market: European Market
5.1 Market Overview
5.2 Market Forecasts
5.3 Average Cost of Therapy
5.4 Volume
5.5 Usage Patterns
5.5.1 Diseased Population
5.5.2 Treatment Seeking Population
5.5.3 Diagnosis Population
5.5.4 Prescription Population
5.5.5 Usage Patterns
6 Global Cardiovascular Therapeutics Market : Japan Market
6.1 Market Forecasts
6.2 Average Cost of Therapy
6.3 Volume
6.4 Usage Patterns
6.4.1 Diseased Population
6.4.2 Treatment Seeking Population
6.4.3 Prescription Population
6.4.4 Usage Patterns
7 Global Hypertension Therapeutics Market
7.1 Market Forecasts
7.2 Average Cost of Therapy
7.3 Volume
7.4 Usage Patterns
7.4.1 Diseased Population
7.4.2 Treatment Seeking Population
7.4.3 Diagnosis Population
7.4.4 Prescription Population
7.4.5 Usage Patterns
8 Global Dyslipidemia Therapeutics Market
8.1 Market Forecasts
8.2 Average Cost of Therapy
8.3 Volume
8.4 Usage Patterns
8.4.1 Diseased Population
8.4.2 Treatment Seeking Population
8.4.3 Diagnosis Population
8.4.4 Prescription Population
8.4.5 Usage Patterns
9 Global Thrombosis Therapeutics Market
9.1 Market Forecasts
9.2 Volume
9.3 Average Cost of Therapy
9.4 Usage Patterns
9.4.1 Diseased Population
9.4.2 Treatment Seeking Population
9.4.3 Diagnosis Population
9.4.4 Prescription Population
9.4.5 Usage Patterns
10 Global Cardiovascular Therapeutics Market: Market Drivers and Restraints
10.1 Market Drivers
10.1.1 Steady Increase in the Elderly Population
10.1.2 Stable Increase in Incidence Rates for Cardiovascular Diseases
10.1.3 Increase in Awareness Levels of Disease Progression and Etiology
10.2 Market Restraints
10.2.1 Patent Expirations and Entry of Generics Pose a Serious Problem for Primary Manufacturers
10.2.2 Reimbursement Restrictions on Drug Classes for Certain Cardiovascular Disease Drug Classes Restricts the Market Growth
11 Global Cardiovascular Therapeutics Market : Unmet Needs
12 Global Cardiovascular Therapeutics Market : Key Market Trends
12.1 Increase in Disease Incidence and Prevalence Rates
12.2 Product Pipeline
12.3 Advertising and Commercialization
12.4 Regulatory trends – Current Reimbursement Scenario
12.4.1 The Budget Impact on Drug Reimbursements
12.4.2 Reliability of Generic Formulations as a Cost Cutting Measure
13 Global Cardiovascular Therapeutics Market: Competitive Landscape
13.1 Overview
13.2 Market Share Analysis
13.3 Competitive Profiling
13.3.1 Pfizer
13.3.2 Sanofi-Aventis
13.3.3 Merck
13.3.4 Novartis
14 Global Cardiovascular Therapeutics Market: M&A Landscape
14.1 Mergers and Acquisitions
14.1.1 Overview
14.2 Licensing Agreements
14.2.1 Research Phase
14.2.2 Preclinical
14.2.3 Phase I
14.2.4 Phase PI/II
14.2.5 Phase II
14.2.6 Phase III
14.2.7 Filed
15 Global Cardiovascular Therapeutics Market : Appendix
15.1 Market Definitions
15.2 Abbreviations
15.3 Research Methodology
15.3.1 Coverage
15.3.2 Secondary Research
15.3.3 Forecasts
15.3.4 Primary Research
15.3.5 Expert Panels
15.4 Contact Us
15.5 Disclaimer
List of Tables:
Table 1: Global Cardiovascular Therapeutics Market, Historical Revenues ($m), 2000-2008
Table 2: Global Cardiovascular Therapeutics Market, Revenue Forecasts ($m), 2008-2015
Table 3: Global Cardiovascular Therapeutics Market, Revenue Segmentation, 2000-2008
Table 4: Global Cardiovascular Therapeutics Market, Revenue Segmentation, 2008-2015
Table 5: Global Cardiovascular Therapeutics Market, Historical Figures for Average Cost of Therapy ($), 2000-2008
Table 6: Global Cardiovascular Therapeutics Market, Historical Figures for Average Cost of Therapy ($), 2008-2015
Table 7: Global Cardiovascular Therapeutics Market, Historical Figures for Volume, 00-08
Table 8: Global Cardiovascular Therapeutics Market, Forecasts for Volume, 2008-2015
Table 9: Global Cardiovascular Therapeutics Market, Historical Figures for Diseased Population, 2000-2008
Table 10: Global Cardiovascular Therapeutics Market, Forecasts for Diseased Population , 2008-2015
Table 11: Global Cardiovascular Therapeutics Market, Historical Figures for Treatment Seeking Population, 2000-2008
Table 12: Global Cardiovascular Therapeutics Market, Forecasts for Treatment Seeking Population, 2008-2015
Table 13: Global Cardiovascular Therapeutics Market, Historical Figures for Diagnosis Population, 2000-2008
Table 14: Global Cardiovascular Therapeutics Market, Forecasts for Diagnosis Population, 2008-2015
Table 15: Global Cardiovascular Therapeutics Market, Historical Figures for Prescription Population, 2000-2008
Table 16: Global Cardiovascular Therapeutics Market, Forecasts for Prescription Population, 2008-2015
Table 17: Global Cardiovascular Therapeutics Market, Historical Figures for Usage Patterns, 2000-2008
Table 18: Global Cardiovascular Therapeutics Market, Forecasts for Usage Patterns, 2008-2015
Table 19: US Cardiovascular Therapeutics Market, Historical Revenues ($m), 2000-2008
Table 20: US Cardiovascular Therapeutics Market, Revenue Forecasts ($m), 2008-2015
Table 21: US Cardiovascular Therapeutics Market, Historical Figures for the Average Cost of Therapy ($), 2000-2008
Table 22: US Cardiovascular Therapeutics Market, Forecasts for the Average Cost of Therapy ($), 2008-2015
Table 23: US Cardiovascular Therapeutics Market, Historical Figures for Volume, 2000-2008
Table 24: US Cardiovascular Therapeutics Market, Forecasts for Volume, 2008-2015
Table 25: US Cardiovascular Therapeutics Market, Historical Figures for Diseased Population, 2000-2008
Table 26: US Cardiovascular Therapeutics Market, Forecasts for Diseased Population, 2008-2015
Table 27: US Cardiovascular Therapeutics Market, Historical Figures for Treatment Seeking Population, 2000-2008
Table 28: US Cardiovascular Therapeutics Market, Forecasts for Treatment Seeking Population, 2008-2015
Table 29: US Cardiovascular Therapeutics Market, Historical Figures for Diagnosis Population(000’), 2000-2008
Table 30: US Cardiovascular Therapeutics Market, Forecasts for Diagnosis Population(000’), 2008-2015
Table 31: US Cardiovascular Therapeutics Market, Historical Figures for Prescription Population, 2000-2008
Table 32: US Cardiovascular Therapeutics Market, Forecasts for Prescription Population, 2008-2015
Table 33: US Cardiovascular Therapeutics Market, Historical Figures for Usage Patterns, 2000-2008
Table 34: US Cardiovascular Therapeutics Market, Forecasts for Usage Patterns, 2008-2015
Table 35: European Cardiovascular Therapeutics Market, Historical Revenues ($bn), 2000-2008
Table 36: European Cardiovascular Therapeutics Market, Revenue Forecasts ($m), 2008-2015
Table 37: European Cardiovascular Therapeutics Market, Historical Figures for Average Cost of Treatment, 2000-2008
Table 38: European Cardiovascular Therapeutics Market, Forecasts for Average Cost of Treatment, 2008-2015
Table 39: European Cardiovascular Therapeutics Market, Historical Figures for Volume, 2000-2008
Table 40: European Cardiovascular Therapeutics Market, Forecasts for Volume, 2008-2015
Table 41: European Cardiovascular Therapeutics Market, Historical Figures for Diseased Population, 2000-2008
Table 42: European Cardiovascular Therapeutics Market, Forecasts for Diseased Population, 2008-2015
Table 43: European Cardiovascular Therapeutics Market, Historical Figures for Treatment Seeking Population, 2000-2008
Table 44: European Cardiovascular Therapeutics Market, Forecasts for Treatment Seeking Population, 2008-2015
Table 45: European Cardiovascular Therapeutics Market, Historical Figures for Diagnosis Population, 2000-2008
Table 46: European Cardiovascular Therapeutics Market, Forecasts for Diagnosis Population, 2008-2015
Table 47: European Cardiovascular Therapeutics Market, Historical Figures for Prescription Population, 2000-2008
Table 48: European Cardiovascular Therapeutics Market, Forecasts for Prescription Population, 2008-2015
Table 49: European Cardiovascular Therapeutics Market, Historical Figures for Usage Patterns, 2000-2008
Table 50: European Cardiovascular Therapeutics Market, Forecasts for Usage Patterns, 2008-2015
Table 51: Japan Cardiovascular Therapeutics Market, Historical Revenues ($m), 2000-2008
Table 52: Japan Cardiovascular Therapeutics Market, Revenue Forecasts ($m), 2008-2015
Table 53: Japan Cardiovascular Therapeutics Market, Historical Figures for Average Cost of Therapy ($), 2000-2008
Table 54: Japan Cardiovascular Therapeutics Market, Forecasts for Average Cost of Therapy ($), 2008-2015
Table 55: Japan Cardiovascular Therapeutics Market, Historical Figures for Volume, 2000-2008
Table 56: Japan Cardiovascular Therapeutics Market, Forecasts for Volume, 2008-2015
Table 57: Japan Cardiovascular Therapeutics Market, Historical Figures for Diseased Population, 2000-2008
Table 58: Japan Cardiovascular Therapeutics Market, Forecasts for Diseased Population, 2008-2015
Table 59: Japan Cardiovascular Therapeutics Market, Historical Figures for Treatment Seeking Population, 2000-2008
Table 60: Japan Cardiovascular Therapeutics Market, Forecasts for Treatment Seeking Population, 2008-2015
Table 61: Japan Cardiovascular Therapeutics Market, Historical Figures for Diagnosis Population, 2000-2008
Table 62: Japan Cardiovascular Therapeutics Market, Forecasts for Diagnosis Population, 2008-2015
Table 63: Japan Cardiovascular Therapeutics Market, Historical Figures for Prescription Population, 2000-2008
Table 64: Japan Cardiovascular Therapeutics Market, Forecasts for Prescription Population, 2008-2015
Table 65: Japan Cardiovascular Therapeutics Market, Historical Figures for Usage Patterns, 2000-2008
Table 66: Japan Cardiovascular Therapeutics Market, Forecasts for Usage Patterns, 2008-2015
Table 67: Global Hypertension Therapeutics Market, Historical Revenues ($m), 2000-2008
Table 68: Global Hypertension Therapeutics Market, Revenue Forecasts ($m), 2008-2015
Table 69: Global Hypertension Therapeutics Market, Historical Figures for the Average Cost of Therapy ($), 2000-2008
Table 70: Global Hypertension Therapeutics Market, Forecast Figures for the Average Cost of Therapy ($), 2008-2015
Table 71: Global Hypertension Therapeutics Market, Historical Figures for Volume, 2000-2008
Table 72: Global Hypertension Therapeutics Market, Forecasts for Volume, 2008-2015
Table 73: Global Hypertension Therapeutics Market, Historical Figures for Diseased Population, 2000-2008
Table 74: Global Hypertension Therapeutics Market, Forecasts for Diseased Population, 2008-2015
Table 75: Global Hypertension Therapeutics Market, Historical Figures for Treatment Seeking Population, 2000-2008
Table 76: Global Hypertension Therapeutics Market, Forecasts for Treatment Seeking Population, 2008-2015
Table 77: Global Hypertension Therapeutics Market, Historical Figures for Diagnosis Population, 2000-2008
Table 78: Global Hypertension Therapeutics Market, Forecasts for Diagnosis Population, 2008-2015
Table 79: Global Hypertension Therapeutics Market, Historical Figures for Prescription Population, 2000-2008
Table 80: Global Hypertension Therapeutics Market, Forecasts for Prescription Population, 2008-2015
Table 81: Global Hypertension Therapeutics Market, Historical Figures for Usage Patterns, 2000-2008
Table 82: Global Hypertension Therapeutics Market, Forecasts for Usage Patterns, 2008-2015
Table 83: Global Dyslipidemia Therapeutics Market, Historical Revenues ($m), 2000-2008
Table 84: Global Dyslipidemia Therapeutics Market, Revenue Forecasts ($m), 2008-2015
Table 85: Global Dyslipidemia Therapeutics Market, Historical Figures for the Average Cost of Therapy ($), 2000-2008
Table 86: Global Dyslipidemia Therapeutics Market, Forecast Figures for the Average Cost of Therapy ($), 2008-2015
Table 87: Global Dyslipidemia Therapeutics Market, Historical Figures for Volume, 2000-2008
Table 88: Global Dyslipidemia Therapeutics Market, Forecasts for Volume, 2008-2015
Table 89: Global Dyslipidemia Therapeutics Market, Historical Figures for Diseased Population, 2000-2008
Table 90: Global Dyslipidemia Therapeutics Market, Forecasts for Diseased Population, 2008-2015
Table 91: Global Dyslipidemia Therapeutics Market, Historical Figures for Treatment Seeking Population, 2000-2008
Table 92: Global Dyslipidemia Therapeutics Market, Forecasts for Treatment Seeking Population, 2008-2015
Table 93: Global Dyslipidemia Therapeutics Market, Historical Figures for Diagnosis Population, 2000-2008
Table 94: Global Dyslipidemia Therapeutics Market, Forecasts for Diagnosis Population, 2008-2015
Table 95: Global Dyslipidemia Therapeutics Market, Historical Figures for Prescription Population, 2000-2008
Table 96: Global Dyslipidemia Therapeutics Market, Forecasts for Prescription Population, 2008-2015
Table 97: Global Dyslipidemia Therapeutics Market, Historical Figures for Usage Patterns, 2000-2008
Table 98: Global Dyslipidemia Therapeutics Market, Forecasts for Usage Patterns, 2008-2015
Table 99: Global Thrombosis Therapeutics Market, Historical Revenues ($m), 2000-2008
Table 100: Global Thrombosis Therapeutics Market, Revenue Forecasts ($m), 2008-2015
Table 101: Global Thrombosis Therapeutics Market, Historical Figures for Volume, 2000-2008
Table 102: Global Thrombosis Therapeutics Market, Forecasts for Volume, 2008-2015
Table 103: Global Thrombosis Therapeutics Market, Historical Figures for Average Cost of Therapy ($), 2000-2008
Table 104: Global Thrombosis Therapeutics Market, Forecasts for Average Cost of Therapy ($), 2008-2015
Table 105: Global Thrombosis Therapeutics Market, Historical Figures for Diseased Population, 2000-2008
Table 106: Global Thrombosis Therapeutics Market, Forecast Figures for Diseased Population, 2008-2015
Table 107: Global Thrombosis Therapeutics Market, Historical Figures for Treatment Seeking Population, 2000-2008
Table 108: Global Thrombosis Therapeutics Market, Forecasts for Treatment Seeking Population, 2008-2015
Table 109: Global Thrombosis Therapeutics Market, Historical Figures for Diagnosis Population, 2000-2008
Table 110: Global Thrombosis Therapeutics Market, Forecasts for Diagnosis Population, 2008-2015
Table 111: Global Thrombosis Therapeutics Market, Historical Figures for Prescription Population, 2000-2008
Table 112: Global Thrombosis Therapeutics Market, Forecasts for Prescription Population, 2008-2015
Table 113: Global Thrombosis Therapeutics Market, Historical Figures for Usage Patterns, 2000-2008
Table 114: Global Thrombosis Therapeutics Market, Forecasts for Usage Patterns, 2008-2015
Table 115: Global Cardiovascular Therapeutics Market, Market Drivers, 2008
Table 116: Global Cardiovascular Therapeutics Market, Market Restraints, 2008
Table 117: Global Cardiovascular Therapeutics Market, Major Drug Patent Expirations, 2008-2015
Table 118:Global Cardiovascular Therapeutics Market, Licensing Agreements for Drugs in the Research Stage, 2008-2009
Table 119: Global Cardiovascular Therapeutics Market, Licensing Agreements for Drugs in the Pre-clinical Stage, 2008-2009
Table 120: Global Cardiovascular Therapeutics Market, Licensing Agreements for Drugs in the PI Stage, 2008-2009
Table 121: Global Cardiovascular Therapeutics Market, Licensing Agreements for Drugs in the PI/PII Stage, 2008-2009
Table 122: Global Cardiovascular Therapeutics Market, Licensing Agreements for Drugs in the PII Stage, 2008-2009
Table 123: Global Cardiovascular Therapeutics Market, Licensing Agreements for Drugs in the PIII stage, 2008-2009
Table 124: Global Cardiovascular Therapeutics Market, Licensing Agreements for Drugs in the Filed Stage, 2008-2009
List of Figures:
Figure 1: Global Cardiovascular Therapeutics Market, Revenue Forecast, 2000-2015
Figure 2: Global Cardiovascular Therapeutics Market, Revenue Segmentation, 2000-2015
Figure 3: Global Cardiovascular Therapeutics Market, Average Cost of Therapy ($), 2000-2015
Figure 4: Global Cardiovascular Therapeutics Market, Volume, 2000-2015
Figure 5: Global Cardiovascular Therapeutics Market, Global Diseased Population, 2000-2015
Figure 6: Global Cardiovascular Therapeutics Market, Forecasts for Treatment Seeking Population, 2000-2015
Figure 7: Global Cardiovascular Therapeutics Market, Forecasts for Diagnosis Population, 2000-2015
Figure 8: Global Cardiovascular Therapeutics Market, Forecasts for Prescription Population, 2000-2015
Figure 9: Cardiovascular Therapeutics Market, Global, Forecasts for Treatment Patterns, 2000-2015
Figure 10: Global Cardiovascular Therapeutics Market, Geographical Distribution of Revenues ($bn), 2000-2015
Figure 11: US Cardiovascular Therapeutics Market, Revenue Forecasts ($bn), 2000-2015
Figure 12: US Cardiovascular Therapeutics Market, Average Cost of Therapy ($), 2000-2015
Figure 13: US Cardiovascular Therapeutics Market, Volume (million), 2000-2015
Figure 14: US Cardiovascular Therapeutics Market, Forecasts for Diseased Population, 2000-2015
Figure 15: US Cardiovascular Therapeutics Market, Forecasts for Treatment Seeking Population, 2000-2015
Figure 16: US Cardiovascular Therapeutics Market, Forecasts for Diagnosis Population, 2000-2015
Figure 17: US Cardiovascular Therapeutics Market, Forecasts for Prescription Population, 2000-2015
Figure 18: US Cardiovascular Therapeutics Market, Forecasts for Usage Patterns, 2000-2015
Figure 19: European Cardiovascular Therapeutics Market, Revenue Forecasts ($bn), 2000-2015
Figure 20: European Cardiovascular Therapeutics Market, Forecasts for Average Cost of Treatment ($), 2000-2015
Figure 21: European Cardiovascular Therapeutics Market, Forecasts for Volume, 2000-2015
Figure 22: European Cardiovascular Therapeutics Market, Forecasts for Diseased Population, 2000-2015
Figure 23: European Cardiovascular Therapeutics Market, Forecasts for Treatment Seeking Population, 2000-2015
Figure 24: European Cardiovascular Therapeutics Market, Forecasts for Diagnosis Population, 2000-2015
Figure 25: European Cardiovascular Therapeutics Market, Forecasts for Prescription Population, 2000-2015
Figure 26: European Cardiovascular Therapeutics Market, Forecasts for Usage Patterns, 2000-2015
Figure 27: Japan Cardiovascular Therapeutics Market, Revenue Forecasts ($bn), 2000-2015
Figure 28: Japan Cardiovascular Therapeutics Market, Forecasts for Average Cost of Therapy ($), 2000-2015
Figure 29: Japan Cardiovascular Therapeutics Market, Forecasts for Volume, 2000-2015
Figure 30: Japan Cardiovascular Therapeutics Market, Forecasts for Diseased Population, 2000-2015
Figure 31: Japan Cardiovascular Therapeutics Market, Forecasts for Treatment Seeking Population, 2000-2015
Figure 32: Japan Cardiovascular Therapeutics Market, Forecasts for Diagnosis Population, 2000-2015
Figure 33: Japan Cardiovascular Therapeutics Market, Forecasts for Prescription Population, 2000-2015
Figure 34: Japan Cardiovascular Therapeutics Market, Forecasts for Usage Patterns, 2000-2015
Figure 35: Global Hypertension Therapeutics Market, Revenue Forecasts ($bn), 2000-2015
Figure 36: Global Hypertension Therapeutics Market, Average Cost of Therapy ($), 2000-2015
Figure 37: Global Hypertension Therapeutics Market, Volume, 2000-2015
Figure 38: Global Hypertension Therapeutics Market, Forecasts for Diseased Population, 2000-2015
Figure 39: Global Hypertension Therapeutics Market, Forecasts for Treatment Seeking Population, 2000-2015
Figure 40: Global Hypertension Therapeutics Market, Forecasts for Diagnosis Population, 2000-2015
Figure 41: Global Hypertension Therapeutics Market, Forecasts for Prescription Population, 2000-2015
Figure 42: Global Hypertension Therapeutics Market, Forecasts for Usage Patterns, 2000-2015
Figure 43: Global Dyslipidemia Therapeutics Market, Revenue Forecasts ($bn), 2000-2015
Figure 44: Global Dyslipidemia Therapeutics Market, Average Cost of Therapy ($), 2000-2015
Figure 45: Global Dyslipidemia Therapeutics Market, Volume, 2000-2015
Figure 46: Global Dyslipidemia Therapeutics Market, Forecasts for Diseased Population, 2000-2015
Figure 47: Global Dyslipidemia Therapeutics Market, Forecasts for Treatment Seeking Population, 2000-2015
Figure 48: Global Dyslipidemia Therapeutics Market, Forecasts for Diagnosis Population, 2000-2015
Figure 49: Global Dyslipidemia Therapeutics Market, Forecasts for Prescription Population, 2000-2015
Figure 50: Global Cardiovascular Therapeutics Market, Forecasts for Treatment Patterns, 2000-2015
Figure 51: Global Thrombosis Therapeutics Market, Revenue Forecasts ($bn), 2000-2015
Figure 52: Global Thrombosis Therapeutics Market, Volume, 2000-2015
Figure 53: Global Thrombosis Therapeutics Market, Forecasts for Average Cost of Therapy ($), 2000-2015
Figure 54: Global Thrombosis Therapeutics Market, Forecasts for Diseased Population, 2000-2015
Figure 55: Global Thrombosis Therapeutics Market, Forecasts for Treatment Seeking Population, 2000-2015
Figure 56: Global Thrombosis Therapeutics Market, Forecasts for Diagnosis Population, 2000-2015
Figure 57: Global Thrombosis Therapeutics Market, Forecasts for Prescription Population, 2000-2015
Figure 58: Global Thrombosis Therapeutics Market, Forecasts for Treatment Patterns, 2000-2015
Figure 59: Global Cardiovascular Disease Therapeutics Market, Market Indicators, 2008
Figure 60: Global Cardiovascular Therapeutics Market, Analysis of Unmet Needs for Major Disease Sectors, 2008
Figure 61: Global Cardiovascular Disease Therapeutics Market, Key Market Events, 2008-2015
Figure 62: Global Cardiovascular Therapeutics Market, Market Share of Top Manufacturers, 2008
Figure 63: Global Cardiovascular Therapeutics Market, Benchmarking Analysis for Top Four Manufacturers, 2008
Figure 64: Global Cardiovascular Therapeutics Market, Benchmarking Analysis for Top Four Manufacturers (Cont..), 2008
Figure 65: Global Cardiovascular Therapeutics Market, M&A Deals by Geography, 2008
Figure 66: Global Cardiovascular Therapeutics Market, M&A Deals by Deal Size, 2008
Figure 67: Global Cardiovascular Therapeutics Market, M&A Deals by Phase, 2008
Figure 68: Global Cardiovascular Therapeutics Market, Top Three M&A Deals, 2008
Figure 69: Global Cardiovascular Therapeutics Market, Licensing Agreement by Geography, 2008
Figure 70: Global Cardiovascular Therapeutics Market, Licensing Agreement by Deal Size, 2008
Figure 71: Global Cardiovascular Therapeutics Market, Licensing Agreements by Phase of Development, 2008
Figure 72: Global Cardiovascular Therapeutics Market, Licensing Agreement by Indications, 2008
Figure 73: GBI Research Methodology
Figure 74: Global Oncology Therapeutics Market Forecasting Model
“The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis” provides insights on the cardiovascular market potential, actual sales, actual volume and price forecasts to 2015. The report also delves deep into the cardiovascular market potential in various indications such as hypertension, dyslipidemia and thrombosis. The report also provides insights into the cardiovascular R&D pipeline. The report also elucidates the cardiovascular competitive landscape including benchmarking of leading companies. Finally, the key trend analysis on mergers and acquisitions, and licensing agreements involving cardiovascular was also provided.
Patent Expiries Coupled with Generic Competition are Negatively Impacting the Market.
The global cardiovascular therapeutics market was valued at $76 billion in 2008 and expected to fall to $67 billion with a CAGR of -1.7% by 2015. Approximately 127 million patients received pharmacological treatment for cardiovascular diseases. The patient volume appears to be increasing at a slow rate. In addition, the average annual cost of therapy for the cardiovascular diseases therapeutic area appears likely to increase at a gradual rate over the next 1-2 years with an expected price decline from 2011 onwards. As a result, the cardiovascular diseases market value is going to see a decline over the time period 2008-2015.
Unmet Need in Cardiovascular Therapeutics Market is Low, Except for Antithrombosis Indication
Cardiovascular diseases disorders such as hypertension and dyslipidemia are currently one of the most explored therapeutic areas. The market is filled with several drug classes that are both safe and effective. There is not any serious unmet need for these indications. The antithrombotic market is in need of an effective replacement for Warfarin. New oral thrombin and factor Xa inhibitors are expected to produce more predictable anticoagulant responses than Warfarin, eliminating the need for regular monitoring and dose adjustments.
Increasing Cost of Novel Drug Development, Declining Market Size and Shrinking Target Population are Forcing Top Companies to Exit the Segment.
Pfizer, the leader in cardiovascular diseases has decided to exit from this segment due to its failure to develop any novel drug coupled with concerns over patent expiries. The growth of generics could be one reason because generic producers spend nothing on R&D thereby hampering the innovative drug discovery process. In licensing, mergers and acquisitions and partnerships are some of the strategies commonly used by the pharmaceutical companies to overcome the drying of their pipeline product resourcess.
Pfizer has entered into an agreement with two Indian companies, Aurobindo Pharmaceuticals and Claris Lifesciences, boosting its pipeline resource with 60 new products
- Pfizer
- Sanofi-Aventis
- Merck
- Novartis
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
